Best management of irritable bowel syndrome

被引:29
作者
Black, Christopher J. [1 ,2 ]
Ford, Alexander Charles [1 ,2 ]
机构
[1] St James Univ Hosp, Leeds Gastroenterol Inst, Leeds LS9 7TF, W Yorkshire, England
[2] Univ Leeds, Leeds Inst Med Res St Jamess, Leeds, W Yorkshire, England
关键词
irritable bowel syndrome; PLACEBO-CONTROLLED TRIAL; QUALITY-OF-LIFE; IBS-D PATIENTS; PHYSICAL-ACTIVITY; DOUBLE-BLIND; GASTROINTESTINAL SYMPTOMS; EFFICACY; CONSTIPATION; THERAPY; CARE;
D O I
10.1136/flgastro-2019-101298
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Irritable bowel syndrome (IBS) is a common disorder of gut-brain interaction which can have a considerable impact on quality of life. Following diagnosis, timely and evidence-based management is vital to the care of patients with IBS, aiming to improve outcomes, and enhance patient satisfaction. Good communication is paramount, and clinicians should provide a clear explanation about the disorder, with a focus on exploring the patient's own beliefs about IBS, and a discussion of any concerns they may have. It should be emphasised that symptoms are often chronic, and that treatment, while aiming to improve symptoms, may not relieve them completely. Initial management should include simple lifestyle and dietary advice, discussion of the possible benefit of some probiotics, and, if this is unsuccessful, patients can be referred to a dietician for consideration of a low FODMAP (fermentable oligosaccharides, disaccharides, monosaccharides and polyols) diet. Antispasmodics and peppermint oil can be used first-line for the treatment of abdominal pain. If patients fail to respond, central neuromodulators can be used second-line; tricyclic antidepressants should be preferred. Loperamide and laxatives can be used first-line for treating diarrhoea and constipation, respectively. Patients with constipation who fail to respond to laxatives should be offered a trial of linaclotide. For patients with diarrhoea, the 5-hydroxytryptamine- 3 receptor agonists alosetron and ramosetron appear to be the most effective second-line drugs. Where these are unavailable, ondansetron is a reasonable alternative. If medical treatment is unsuccessful, patients should be referred for psychological therapy, where available, if they are amenable to this. Cognitive behavioural therapy and gut-directed hypnotherapy are the psychological therapies with the largest evidence base.
引用
收藏
页码:303 / 315
页数:13
相关论文
共 100 条
[1]   The Dietary Management of Patients with Irritable Bowel Syndrome: A Narrative Review of the Existing and Emerging Evidence [J].
Algera, Joost ;
Colomier, Esther ;
Simren, Magnus .
NUTRIENTS, 2019, 11 (09)
[2]  
Ali A, 2017, BMJ OPEN GASTROENTER, V4, DOI 10.1136/bmjgast-2017-000164
[3]  
[Anonymous], 2016, GASTROENTEROLOGY
[4]   Faecal incontinence-the hidden scourge of irritable bowel syndrome: a cross-sectional study [J].
Atarodi, Sima ;
Rafieian, Shahram ;
Whorwell, Peter J. .
BMJ OPEN GASTROENTEROLOGY, 2014, 1 (01)
[5]   Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial [J].
Atkinson, W ;
Sheldon, TA ;
Shaath, N ;
Whorwell, PJ .
GUT, 2004, 53 (10) :1459-1464
[6]   A randomized, double-blind, placebo-controlled trial of polyethylene glycol effects on fasting and postprandial rectal sensitivity and symptoms in hypersensitive constipation-predominant irritable bowel syndrome [J].
Awad, R. A. ;
Camacho, S. .
COLORECTAL DISEASE, 2010, 12 (11) :1131-1138
[7]  
*B D A, 2019, IRR BOW SYNDR DIET F
[8]  
Bertram S, 2001, J FAM PRACTICE, V50, P521
[9]   Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis [J].
Black, Christopher J. ;
Thakur, Elyse R. ;
Houghton, Lesley A. ;
Quigley, Eamonn M. M. ;
Moayyedi, Paul ;
Ford, Alexander C. .
GUT, 2020, 69 (08) :1441-+
[10]   Rational investigations in irritable bowel syndrome [J].
Black, Christopher J. ;
Ford, Alexander C. .
FRONTLINE GASTROENTEROLOGY, 2020, 11 (02) :140-147